Omeprazole: Its Influence on Gastric Acid Secretion,Gastrin and ECL Cells

Abstract

The H⁺,K⁺-ATPase inhibitor omeprazole is a highly effective gastric antisecretory agent, both in animals and man, with a long duration of action. These properties are shared by a number of recently described histamine H₂-receptor antagonists. In life-long oncogenicity studies of these H₂-receptor antagonists, as well as with the H⁺,K⁺-ATPase inhibitor omeprazole, gastric enterochromaffin-like cell (ECL cell) hyperplasia and carcinoids have been found. The purpose of this paper is to summarize available evidence for the “Gastrin Hypothesis” to explain the development of ECL-cell hyperplasia. The hypothesis may be outlined as follows: 1) Inhibition of gastric acid secretion leads to elevated antral pH and, secondarily, to release of gastrin from the antral gastrin cells into the blood stream. 2) Gastrin causes both general hypertrophy of the oxyntic mucosa and hyperplasia of the ECL cells in the oxyntic mucosa. That this sequence of events occurs not only with omeprazole but also with other effective gastric antisecretory agents has been verified in the rat by giving the H₂-receptor antagonist ranitidine as a continuous infusion. Ranitidine caused a hypergastrinemia of a similar magnitude as that seen after omeprazole, provided that the acid secretion was inhibited to a similar degree. At similar gastrin levels, ECL-cell hyperplasia of the same magnitude developed during both ranitidine and omeprazole treatment. Antrectomy prevented the development of ECL-cell hyperplasia during omeprazole treatment, indicating that the hyperplasia was not due to the drug treatment per se, but rather to the hypergastrinemia. Both the hypergastrinemia and the ECL-cell hyperplasia were found to be reversible. Control plasma gastrin levels were reached within a few days of stopping long-term treatment, and the ECL-cell density was back to normal 20 weeks after discontinuing 10 weeks of treatment with high-dose omeprazole. We conclude from these studies that the ECL-cell hyperplasia seen in rats after long-term treatment with gastric acid secretion inhibitors is reversible and secondary to the hypergastrinemia, and is not caused by the drugs per se. Furthermore, although the gastrin mechanism for the regulation of the ECL cells seems to be similar in different species, there are quantitative differences with regard to the ECL-cell density and possibly also the sensitivity of ECL cells to gastrin.

References

1. Allen JM , Bishop AE , Daly MJ , Larsson H , Carlsson E , Polak JM , and Bloom SR (1986). Effect of inhibition of acid secretion on the regulatory peptides in the rat stomach. Gastroenterology 90: 970–977.

2. Blom H (1986). Alterations in gastric mucosal morphology induced by long-term treatment with omeprazole in rats. Digestion (Suppl. 1) 35: 98–105.

3. Bordi C , Ravazzola M , and DeVita O (1983). Pathology of endocrine cells in gastric mucosa. Ann. Pathol. 3: 19–28.

4. Creutzfeldt W , Stöckmann F , Conlon JM , Fölsch UR , Bonatz G , and Wülfrath M (1986). Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion (Suppl. 1) 35: 84–97.

5. Crean GP , Daniel D , Leslie GB , and Bates C (1978). The effects of prolonged administration of large doses of cimetidine on the gastric mucosa of rats. In: Cimetidine. The Westminster Hospital Symposium, C Wastell and P Lance (eds). Churchill Livingstone, Edinburgh, pp. 191–206.

6. Ekman L , Hanson E , Havu N , Carlsson E , and Lundborg C (1985). Toxicological studies with omeprazole. Scand. J. Gastroenterol. (Suppl. 108) 20: 53–69.

7. Håkanson R , Blom H , Carlsson E , Larsson H , Ryberg B , and Sundler F (1986). Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul. Pept. 13: 223–233.

8. Håkanson R , Böttcher G , Ekblad E , Panula P , Simonsson M , Dohlsten M , Hallberg T , and Sundler F (1986). Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry 86: 5–17.

9. Håkanson R , Böttcher G , Sundler F , and Vallgren S (1986). Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion (Suppl. 1) 35: 23–41.

10.

10. Håkanson R , Oscarson J , and Sundler F (1986). Gastrin and the trophic control of the oxyntic mucosa. Scand. J. Gastroenterol. (Suppl. 118) 21: 18–30.

11.

11. Halter F , Inauen W , Eigenmann F , Varga L , and Koelz HR (1986). Effect of acid inhibition on the growth of parietal cells. Scand. J. Gastroenterol. (Suppl. 125) 21: 9–13.

12.

12. Havu N (1986). Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion. Digestion (Suppl. 1) 35: 42–55.

13.

13. Johnson LR , Aures D , and Håkanson R (1969). Effect of gastrin on the in vivo incorporation of 14C-leucine into protein of the digestive tract. Proc. Soc. Exp. Biol. Med. 132: 996–998.

14.

14. Johnson LR , Aures D , and Yuen L (1969). Pentagastrin induced stimulation of protein synthesis in the gastrointestinal tract. Am. J. Physiol. 217: 251–254.

15.

15. Larsson H , Carlsson E , Mattsson H , Lundell L , Sundler F , Sundell G , Wallmark B , Watanabe T , and Hakanson R (1986). Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90: 391–399.

16.

16. Larsson H , Carlsson E , Ryberg B , Fryklund J , and Wallmark B (1988). Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am. J. Physiol. 254: G33–G39.

17.

17. Larsson H and Ryberg B (1983). Omeprazole increases K+ net flow during stimulated conditions in the mammalian gastric mucosa in vitro. The Physiologist 26 (4): A27.

18.

18. Lindberg P , Nordberg P , Alminger T , Brändström A , and Wallmark B (1986). The mechanism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem. 29: 1327–1329.

19.

19. Mattsson H , Ryberg B , Lundell L , Håkanson R , and Sundler F (1987). Effect of fundectomy on plasma gastrin levels and ECL-cell density in the rat oxyntic mucosa. Gastroenterology 92: 1523 (Abstract).

20.

20. Penston J and Wormsley KG (1987). Achlorhydria: Hypergastrinaemia: Carcinoids–-A flawed hypothe sis? Gut 28: 488–505.

21.

21. Ryberg B , Mattsson H , Sundler F , Håkanson R , and Carlsson E (1986). Effect of inhibition of gastric acid secretion in rats on plasma gastrin levels and density of enterochromaffin-like cells in the oxyntic mucosa. (Abstr no. 174). In: Proceedings from 6th International Symposium on Gastrointestinal Hormones (Vancouver, Canada), J Kraicer and GS Marks (eds). Vancouver, pp. 34–35.

22.

22. Sundell G and Nilsson G (1986). Structure and function of the dog gastric mucosa during and after a 1-year treatment with omeprazole. II. Effects on gastric acid secretion and blood levels of gastric hormones. Scand. J. Gastroenterol. (Suppl. 118) 21: 82–85.

23.

23. Wallmark B , Brändström A , and Larsson H (1984). Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+, K+)-ATPase within the parietal cell. Biochim. Biophys. Acta 778: 549–558.

24.

24. Wallmark B , Carlsson E , Larsson H , Brändström A , and Lindberg P (1986). New inhibitors of gastric acid secretion: Properties and design of H+,K+-ATPase blockers. In: Third SCI-RSC Medicinal Chemistry Symposium, RW Lambert (ed). The Royal Society of Chemistry, London, pp. 293–311.

25.

25. Wallmark B , Jaresten BM , Larsson H , Ryberg B , Brändström A , and Fellenius E (1983). Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN- on gastric acid secretion. Am. J. Physiol. 245: G64–G71.

26.

26. Wallmark B , Larsson H , and Humble L (1985). The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. J. Biol. Chem. 260: 13681–13684.